Summary

Meet our Team at our booth and listen to our Tools and Technology Presentation on May 13 !

Our team

 Mégane Denu 
 R&D Bioproduction Engineer 
About Mégane Denu
R&D Bioproduction Engineer
Aucune information.
 Jonathan Havard 
 R&D Bioproduction Engineer 
About Jonathan Havard
R&D Bioproduction Engineer
Aucune information.
 Mathieu Porte 
 Bioproduction R&D Manager  
About Mathieu Porte
Bioproduction R&D Manager
Aucune information.
 Marine Guise 
 R&D Bioproduction Scientist 
About Marine Guise
R&D Bioproduction Scientist
Aucune information.
 Ashlee Sun 
 Field Application Specialist - AMERICAS 
About Ashlee Sun
Field Application Specialist - AMERICAS
Aucune information.
 Tom KRESGE 
 VP Sales US 
About Tom KRESGE
VP Sales US
Aucune information.
 Julien Depollier 
 Director Strategic Partnerships 
About Julien Depollier
Director Strategic Partnerships
Aucune information.
 Bertrand Coissac 
 Business Director APAC 
About Bertrand Coissac
Business Director APAC
Aucune information.
 Roel Gordijn 
 Chief Commercial Officer 
About Roel Gordijn
Chief Commercial Officer
Aucune information.
 Geraldine Guerin-Peyrou 
 Director of Marketing & Communication 
About Geraldine Guerin-Peyrou
Director of Marketing & Communication
Aucune information.

Talk: Combining highest rAAV manufacturing performance with highest quality standards to support CGT industry

The number of ATMP therapeutic-based medicines for inherited genetic disorders is in constant growth, with a global 32% increase in new clinical trials in the last 4 years. ATMPs have demonstrated their success with already more than ten approved for commercialization. The success of AAV as the most promising viral vector for gene therapy is due to low immunogenicity, broad tropism and non-integrating properties. Today, the key challenge for translation of promising research to clinical development is meeting the growing demands in AAV production, while meeting health authorities’ quality standards to ensure patient safety. Transient transfection is the decisive step to focus on in rAAV manufacturing to significantly boost AAV production capacity. To address this concern, we present data on a FectoVIR®-AAV transfection reagent showing: i) increased AAV titers, ii) improved transfection protocol for large scale bioreactors and iii) reproducible viral titer during scale-up. Furthermore, we demonstrate our continuous commitment to supporting CGT manufacturers by making FectoVIR-AAV available at GMP grade, the highest quality grade for ancillary materials aligned with quality standards recommended by health authorities to ensure patient safety.

Presented by Mathieu PORTE, R&D Bioproduction Manager at Polyplus-transfection®

Thursday May 13th , from 5:15 pm-5:30 pm ET.

 

Poster

Next-Generation Transfection Reagent for Large Scale AAV Manufacturing

Mathieu Porte, Mégane Denu, Jonathan Havard, Marine Ricordel, Coralie Stritt, Yann Philipson, Malik Hellal, Patrick Erbacher

 

Our solutions for both protein and virus production

FectoVIR®-AAV: for Recombinant AAV virus production in suspension cells.

PEIpro® product range for a scalable viral vector production for Gene & Cell therapy.

FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).

General information

Registration link for virtual event: click here
Give your feedback!